537 related articles for article (PubMed ID: 14679273)
1. Screening for proteinuria in US adults: a cost-effectiveness analysis.
Boulware LE; Jaar BG; Tarver-Carr ME; Brancati FL; Powe NR
JAMA; 2003 Dec; 290(23):3101-14. PubMed ID: 14679273
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of screening and optimal management for diabetes, hypertension, and chronic kidney disease: a modeled analysis.
Howard K; White S; Salkeld G; McDonald S; Craig JC; Chadban S; Cass A
Value Health; 2010; 13(2):196-208. PubMed ID: 19878493
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes.
CDC Diabetes Cost-effectiveness Group
JAMA; 2002 May; 287(19):2542-51. PubMed ID: 12020335
[TBL] [Abstract][Full Text] [Related]
4. A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA.
Palmer AJ; Valentine WJ; Chen R; Mehin N; Gabriel S; Bregman B; Rodby RA
Nephrol Dial Transplant; 2008 Apr; 23(4):1216-23. PubMed ID: 18359872
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers as first-line treatment in autosomal dominant polycystic kidney disease.
Clark LA; Whitmire S; Patton S; Clark C; Blanchette CM; Howden R
J Med Econ; 2017 Jul; 20(7):715-722. PubMed ID: 28332417
[TBL] [Abstract][Full Text] [Related]
6. Cost-utility analysis of the National Health Screening Program for chronic kidney disease in Korea.
Go DS; Kim SH; Park J; Ryu DR; Lee HJ; Jo MW
Nephrology (Carlton); 2019 Jan; 24(1):56-64. PubMed ID: 29206319
[TBL] [Abstract][Full Text] [Related]
7. The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors.
Golan L; Birkmeyer JD; Welch HG
Ann Intern Med; 1999 Nov; 131(9):660-7. PubMed ID: 10577328
[TBL] [Abstract][Full Text] [Related]
8. A health policy model of CKD: 2. The cost-effectiveness of microalbuminuria screening.
Hoerger TJ; Wittenborn JS; Segel JE; Burrows NR; Imai K; Eggers P; Pavkov ME; Jordan R; Hailpern SM; Schoolwerth AC; Williams DE;
Am J Kidney Dis; 2010 Mar; 55(3):463-73. PubMed ID: 20116910
[TBL] [Abstract][Full Text] [Related]
9. Screening for type 2 diabetes mellitus: a cost-effectiveness analysis.
Hoerger TJ; Harris R; Hicks KA; Donahue K; Sorensen S; Engelgau M
Ann Intern Med; 2004 May; 140(9):689-99. PubMed ID: 15126252
[TBL] [Abstract][Full Text] [Related]
10. To pay or not to pay? A decision and cost-utility analysis of angiotensin-converting-enzyme inhibitor therapy for diabetic nephropathy.
Clark WF; Churchill DN; Forwell L; Macdonald G; Foster S
CMAJ; 2000 Jan; 162(2):195-8. PubMed ID: 10674051
[TBL] [Abstract][Full Text] [Related]
11. Cost effectiveness of ACE inhibitor treatment for patients with type 1 diabetes mellitus.
Dong FB; Sorensen SW; Manninen DL; Thompson TJ; Narayan V; Orians CE; Gregg EW; Eastman RC; Dasbach EJ; Herman WH; Newman JM; Narva AS; Ballard DJ; Engelgau MM
Pharmacoeconomics; 2004; 22(15):1015-27. PubMed ID: 15449965
[TBL] [Abstract][Full Text] [Related]
12. Visual screening for malignant melanoma: a cost-effectiveness analysis.
Losina E; Walensky RP; Geller A; Beddingfield FC; Wolf LL; Gilchrest BA; Freedberg KA
Arch Dermatol; 2007 Jan; 143(1):21-8. PubMed ID: 17224538
[TBL] [Abstract][Full Text] [Related]
13. The cost effectiveness of ACE inhibitors as first-line antihypertensive therapy.
Nordmann AJ; Krahn M; Logan AG; Naglie G; Detsky AS
Pharmacoeconomics; 2003; 21(8):573-85. PubMed ID: 12751915
[TBL] [Abstract][Full Text] [Related]
14. A cost-effectiveness analysis of screening urine dipsticks in well-child care.
Sekhar DL; Wang L; Hollenbeak CS; Widome MD; Paul IM
Pediatrics; 2010 Apr; 125(4):660-3. PubMed ID: 20231188
[TBL] [Abstract][Full Text] [Related]
15. Population based screening for chronic kidney disease: cost effectiveness study.
Manns B; Hemmelgarn B; Tonelli M; Au F; Chiasson TC; Dong J; Klarenbach S;
BMJ; 2010 Nov; 341():c5869. PubMed ID: 21059726
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of screening for lung cancer with low dose spiral CT (computed tomography) in the Australian setting.
Manser R; Dalton A; Carter R; Byrnes G; Elwood M; Campbell DA
Lung Cancer; 2005 May; 48(2):171-85. PubMed ID: 15829317
[TBL] [Abstract][Full Text] [Related]
17. Lung cancer screening with helical computed tomography in older adult smokers: a decision and cost-effectiveness analysis.
Mahadevia PJ; Fleisher LA; Frick KD; Eng J; Goodman SN; Powe NR
JAMA; 2003 Jan; 289(3):313-22. PubMed ID: 12525232
[TBL] [Abstract][Full Text] [Related]
18. Feasibility study of the early detection and treatment of renal disease by mass screening.
Craig JC; Barratt A; Cumming R; Irwig L; Salkeld G
Intern Med J; 2002; 32(1-2):6-14. PubMed ID: 11783681
[TBL] [Abstract][Full Text] [Related]
19. The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States.
Rein DB; Wittenborn JS; Lee PP; Wirth KE; Sorensen SW; Hoerger TJ; Saaddine JB
Ophthalmology; 2009 May; 116(5):823-32. PubMed ID: 19285730
[TBL] [Abstract][Full Text] [Related]
20. Expanded screening for HIV in the United States--an analysis of cost-effectiveness.
Paltiel AD; Weinstein MC; Kimmel AD; Seage GR; Losina E; Zhang H; Freedberg KA; Walensky RP
N Engl J Med; 2005 Feb; 352(6):586-95. PubMed ID: 15703423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
